3,269 Shares in Pfizer Inc. $PFE Acquired by RMG Wealth Management LLC

RMG Wealth Management LLC acquired a new position in Pfizer Inc. (NYSE:PFE) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,269 shares of the biopharmaceutical company’s stock, valued at approximately $80,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. Miracle Mile Advisors LLC boosted its stake in Pfizer by 6.2% during the 1st quarter. Miracle Mile Advisors LLC now owns 233,234 shares of the biopharmaceutical company’s stock valued at $5,910,000 after purchasing an additional 13,534 shares in the last quarter. Central Bank & Trust Co. boosted its stake in Pfizer by 18.8% during the 1st quarter. Central Bank & Trust Co. now owns 19,869 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 3,140 shares in the last quarter. Finally, AHL Investment Management Inc. boosted its stake in Pfizer by 7.4% during the 1st quarter. AHL Investment Management Inc. now owns 91,782 shares of the biopharmaceutical company’s stock valued at $2,326,000 after purchasing an additional 6,345 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

PFE opened at $26.45 on Tuesday. The stock has a fifty day moving average of $24.72 and a 200-day moving average of $24.12. The firm has a market capitalization of $150.38 billion, a P/E ratio of 14.07, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.